Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
Beijing Biostar Technologies Ltd (HKG: 2563) announced that its wholly‑owned U.S. subsidiary, Biostar Pharma, Inc.,...
HKG: 2563
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...
Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its...
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...